UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

FOR THE QUARTERLY PERIOD ENDED ~~August~~February 3128, ~~2016~~2017

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

COMMISSION FILE NUMBER: 000-55378

iHealthcare, Inc.

(Exact name of registrant as specified in its charter)

Delaware		47-3002847
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
141 NE 3rd Avenue, Miami, FL		33132
3901 NW 28th Street, 2nd Floor, Miami, FL		33142
(Address of principal executive offices)		(Zip Code)

N/A

(Former name if changed since last report)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X]Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X]Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer		[ ]		Accelerated filer		[ ]
	Non-accelerated filer		[ ] (Do not check if a smaller reporting company)		Smaller reporting company		[X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[]Yes [X] No

State the number of shares outstanding of each of the issuer’s classes of common equity, as of ~~October~~April 1719, ~~2016~~2017: 1,~~000~~081,~~000~~480 shares of common stock.

-1-

TABLE OF CONTENTS

(FORMERLY KNOWN AS OPULENT ACQUISITION, INC.)

IHEALTHCARE, INC.

INDEX

PART I-FINANCIAL INFORMATION


ITEM 1	FINANCIAL STATEMENTS

CONSOLIDATED Balance Sheets (unaudited)		F1

consolidated Statements of Operations (unaudited)		F2

CONSOLIDATED Statements of Cash Flows (unaudited)		F3

Notes to Unaudited consolidated Financial Statements		F4

ITEM 2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	3

ITEM 3	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	4

ITEM 4	CONTROLS AND PROCEDURES	4

PART II-OTHER INFORMATION

ITEM 1	LEGAL PROCEEDINGS	4

ITEM 1A	RISK FACTORS

ITEM 2	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	4

ITEM 3	DEFAULTS UPON SENIOR SECURITIES	4

ITEM 4	MINE SAFETY DISCLOSURES	5

ITEM 5	OTHER INFORMATION	5

ITEM 6	EXHIBITS	5

SIGNATURES		5

-2-

Table of Contents

PART I-FINANCIAL INFORMATION

ITEM 1

FINANCIAL STATEMENTS

IHEALTHCARE, INC.

(FORMERLY KNOWN AS OPULENT ACQUISITION, INC.)

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

			As of August 31, 2016				As of November 30, 2015
		As of February 28, 2017			As of November 30, 2016
ASSETS
Current Assets
Cash	$	$4,941	~~547~~	$	33	$	-
Inventory		285	~~285~~		285		-
TOTAL ASSETS		$	832			$	-
Loan to Related Party		1,941			-
LIABILITIES & STOCKHOLDERS’ DEFICIT
TOTAL ASSETS	$	7,167		$	318
Current Liabilities
LIABILITIES & STOCKHOLDERS’ DEFICIT
Accrued expenses		$	4,040			$	3,446
Current Liabilities
Due to related party			10,485				-
Accrued expenses	$	4,235		$	4,629
Total Current Liabilities			14,525				3,446
Due to related party		18,516			13,855
TOTAL LIABILITIES			14,525				3,446
Total Current Liabilities		22,751			18,484
Stockholders’ Deficit
TOTAL LIABILITIES		22,751			18,484
Series A Preferred stock ($.0001 par value, 1,500,000 shares authorized; none issued and outstanding)			-				-
Stockholders’ Deficit
Series B Preferred stock ($.0001 par value, 5,000,000 shares authorized; none issued and outstanding)			-				-
Series A Preferred stock ($.0001 par value, 1,500,000 shares authorized; none issued and outstanding)		-			-
Common stock ($.0001 par value 143,500,000 shares authorized and 1,000,000 outstanding as of August 31, 2016 and November 30, 2015)			100				100
Series B Preferred stock ($.0001 par value, 5,000,000 shares authorized; none issued and outstanding)		-			-
Subscription receivable			(5,500)				-
Common stock ($.0001 par value 143,500,000 shares authorized and 1,079,500 and 1,000,000 outstanding as of February 28, 2017 and November 30, 2016, respectively)		108			100
Additional paid in capital			43,598				8,118
Subscription receivable		(5,500)			(5,500)
Accumulated deficit			(51,891	)			(11,664)
Additional paid in capital		63,465			43,598
Total Stockholders’ Deficit			(13,693)				(3,446)
Accumulated deficit		(73,657)			(56,364)
TOTAL LIABILITIES & STOCKHOLDERS’ DEFICIT		$	832			$	-
Total Stockholders’ Deficit		(15,584)			(18,166)
TOTAL LIABILITIES & STOCKHOLDERS’ DEFICIT	$	7,167		$	318

See Accompanying Notes to Unaudited Consolidated Financial Statements.

-F1-

Table of Contents

iHealthcare, Inc.

FORMERLY KNOWN AS OPULENT ACQUISITION, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

		Three Months Ended August 31, 2016		Three Months Ended August 31, 2015		Nine Months Ended August 31, 2016		Nine Months Ended August 31, 2015
		Three Months Ended February 28, 2017		Three Months Ended February 29, 2016
Revenues	$	~~619~~545	$	-	$	~~619~~	$	-
Cost of Goods Sold		285		-		~~285~~		-
Gross Profit	$	~~334~~260	$	-	$	~~334~~	$	-
Operating Expenses
Organization and Related Expenses	$	~~379~~853	$	-	$	~~2,594~~	$	~~550~~
Professional fees		1016,~~856~~700		14,~~250~~750		~~37,967~~		~~4,000~~
Total operating expenses		1117,~~235~~553		14,~~250~~750		~~40,561~~		~~4,550~~
Net loss	$	(1017,~~901~~293)	$	(14,~~250~~750)	$	~~(40,227)~~	$	~~(4,550)~~
Basic and Diluted net loss per common share	$	(0.01)	$	(0.00)	$	(0.04)	$	(0.00)
Basic and diluted net loss per common share	$	(0.02)	$	(0.00)
Weighted average number of common shares outstanding - Basic and Diluted		1,000,000		1,000,000		1,000,000		1,000,000
Weighted average number of common shares outstanding - basic and diluted		1,018,550		1,000,000

See Accompanying Notes to Unaudited Consolidated Financial Statements.

-F2-

Table of Contents

iHealthcare, Inc.

FORMERLY KNOWN AS Opulent Acquisition, iNC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

		For the Nine Months Ended August 31, 2016	For the Nine Months Ended August 31, 2015
		For the Three Months Ended February 28, 2017		For the Three Months Ended February 29, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(4017,~~227~~293)	$	(4,~~550~~750)
Adjustment to reconcile net loss to net cash used in operating activities:
Expenses contributed to capital		-		4,~~898~~696
Changes in current assets and liabilities:
Increase in inventory		(285)		-
Increase in accrued expenses		1,525		54
Increase (decrease) in accrued expenses		16,869		(348)
Net cash used in operating activities	$	(15,768)	$	-
Net cash used in operating activities	$	(23,643)	$	-
Cash flow from Investing Activities:
Overpayment accounted for as loan to related party	$	(1,941)	$	-
Net cash used in investing activities	$	(1,941)	$	-
CASH FLOWS FROM FINANCING ACTIVITIES
Cash received from related party loan		6,015		-
Proceeds from related party loans		7,643		-
Payment made on related party loan		(34,~~805~~901)		-
Subscription Receivable		21,980		-
Proceeds from the sale of common shares		19,875		-
Net cash provided by Financing Activities	$	2422,~~190~~617	$	-
Increase (Decrease) in cash		547		-
Increase in cash		4,908		-
Beginning cash balance		-33		-
Ending cash balance	$	~~547~~4,941	$	-
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid	$	-	$	-
Income taxes paid	$	-	$	-
NON-CASH INVESTING AND FINANCING ACTIVITIES
SUPPLEMENTAL DISCLOSURES OF NON-CASH INFORMATION:
Netting of subscription receivable against related party loan	$	7,500	$	-
Expenses paid by related party on behalf of the Company	$	1,919	$	-
Subscription receivable contributed in merger	$	34,980	$	-
Due to related party for expenses paid on behalf of the Company	$	16,275	$	-
Forgiveness of related party loan into converted capital	$	500	$	-

See Accompanying Notes to Unaudited Consolidated Financial Statements.

-F3-

Table of Contents

iHealthcare, Inc.

FORMERLY KNOWN AS OPULENT ACQUISITION, InC.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

~~August~~February 3128, ~~2016~~ 2017

~~Note~~NOTE 1 - ~~Organization~~ORGANIZATION ~~and~~AND ~~Description~~DESCRIPTION ofOF ~~Business~~BUSINESS

iHealthcare Inc. (formerly Opulent Acquisition, Inc.) (the Company) was incorporated under the laws of the State of Delaware on November 25, 2014. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business. The Company ~~originally~~ elected November 30th as its year end ~~but has applied to change its fiscal year end to December 31~~. ~~As of now however, the fiscal year is November 30th.~~

On ~~January~~February 1423, ~~2016~~2017 ~~Mr. Jeffrey DeNunzio~~iHealthcare, ~~the~~ ~~sole~~Inc. ~~shareholder~~entered ofinto ~~the~~an agreement ~~Company~~with ~~transferred~~John toCook ~~iHealthcare,~~and ~~Inc~~Paul Pereira., aUnder ~~Florida~~the ~~Company,~~terms ~~20,000,000 shares~~ of ~~our~~the ~~common~~agreement ~~stock which~~John ~~represented~~Cook ~~all~~and ofPaul ~~our~~Pereira ~~issued~~will ~~and~~act ~~outstanding~~as ~~shares~~part ~~at the~~ time consultants offor ~~transfer~~iHealthcare, inInc. ~~consideration~~Their ofrole ~~$25,000.~~shall ~~The~~pertain ~~transfer~~to ~~was~~ assisting the ~~result~~Company ofwith ~~the~~obtaining ~~sale~~and ofstructuring institutional ~~the~~financing ~~Company~~from tovarious ~~iHealthcare,~~commercial ~~Inc.~~banks, ~~the~~investment ~~Florida~~banking ~~Company.~~firms, ~~The~~private ~~result~~equity offirms ~~the~~and ~~January~~related ~~14, 2016 transaction~~financial ~~was~~and ~~iHealthcare,~~business ~~Inc~~issues. ~~(formerly~~John ~~Opulent)~~Cook ~~became~~and ~~the~~Paul ~~wholly~~Pereira ~~owned~~shall ~~subsidiary~~be ofcompensated ~~iHealthcare,~~for ~~Inc.~~their ~~(Florida).~~part ~~Due~~time toassistance ~~management’s~~as consultants through a ~~intent~~combination toof ~~merge~~cash ~~iHealthcare,~~and ~~Inc~~stock incentives. ~~(formerly~~John ~~Opulent)~~Cook and ~~iHealthcare,~~Paul ~~Inc.~~Pereira ~~(Florida)~~shall atbe awarded a ~~later~~total ~~date~~of ~~$34~~10.00%,~~980~~ ~~paid by iHealthcare~~respectively, of ~~Inc.~~Series ~~(Florida)~~B ~~was~~Preferred ~~accounted~~stock ~~for~~based inupon ~~Paid~~acquisition inmilestones. ~~Capital~~The ~~of iHealthcare, Inc~~10.00% ~~(Florida).~~to ~~This~~that ~~was~~point ~~based~~shall onbe aSeries ~~conclusion~~B ~~that~~Preferred ~~iHealthcare~~Stock, ~~Inc.~~however, ~~(formerly~~if ~~Opulent)~~they ~~would~~assist ~~not~~the ~~qualify~~Company asin aachieving ~~business~~gross ~~under~~revenues ~~ASC~~exceeding ~~805~~$200,000,000 ~~due~~then tothey ~~iHealthcare,~~will ~~Inc.’s~~each ~~(formerly~~be ~~Opulent)~~awarded ~~lack~~an ofextra ~~assets,~~2.5% ~~operations,~~of ~~inputs or processes at~~ the ~~acquisition~~Preferred ~~date.~~Stock ~~The~~in ~~use~~a ofnew ~~Fair~~class ~~Value~~with ~~and~~the ~~purchase~~same ~~accounting~~rights ~~did~~as ~~not~~Series ~~appear appropriate~~B. ~~considering~~This ~~the~~would ~~aforementioned~~bring ~~facts~~their ~~and~~total ~~management’s~~equity interest ~~intent~~ to ~~merge the entities~~12.50% ~~Management~~each, ~~took~~and a25.00% ~~view~~total. No ~~at the~~milestones ~~acquisition~~have ~~date~~been ~~towards~~achieved ~~805-50~~ and ~~the~~no ~~eventual~~shares ~~use~~ of ~~the~~preferred stock ~~rules~~issued ~~covering~~as ~~a merger~~ of ~~entities~~February ~~under~~28, ~~common control~~2017.

~~On January 14, 2016 iHealthcare, Inc.,~~NOTE a2 ~~Florida~~- ~~Company,~~SUMMARY ~~became~~OF ~~the~~SIGNIFICANT ~~controlling~~ACCOUNTING shareholder of Opulent Acquisition, Inc. At the time of the sale of Opulent Acquisition, Inc. Mr. Mijares owned 62.5% and Mr. Bingaman owned 37.5% of the issued and outstanding shares of iHealthcare, Inc., the Florida Company.POLICIES

On January 14, 2016, Mr. Jeffrey DeNunzio resigned as Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer and Director of Opulent Acquisition, Inc.

On January 14, 2016, Mr. Noel Mijares was appointed as Chairman of the Board of Directors, Chief Executive Officer, and President.

On January 14, 2016, Mr. David A. Bingaman was appointed as Chief Operating Officer, Vice President, and Secretary.

On April 22, 2016 we, Opulent Acquisition, Inc. (“iHealthcare, Inc.-Delaware”) entered into and consummated a merger with iHealthcare, Inc., a Florida Company (“iHealthcare, Inc.-Florida”). iHealthcare, Inc.-Delaware is the Surviving Corporation as result of the merger. The officers and directors of Opulent Acquisition, Inc., now known as iHealthcare, Inc., remained the same and unchanged.

On April 22, 2016, iHealthcare, Inc. (formerly Opulent) and iHealthcare, Inc. (Florida) were under common control. iHealthcare, Inc. (formerly Opulent) was 100% owned by iHealthcare, Inc. (Florida). Due to the parent subsidiary relationship on April 22, 2016, under ASC 805-50, the transaction is being accounted for similar to a pooling of interests with carryover basis being used and go forward reporting will have the entities combined from the first day of the first period presented.

On April 22, 2016, the Company filed with the Delaware Secretary of State an amendment to the Company’s certificate of incorporation, changing its name to iHealthcare, Inc.

Previous to the Merger Noel Mijares owned 6,250 shares of common stock of iHealthcare, Inc., the Florida Company and David A Bingaman owned 3,750 shares of common stock of iHealthcare, Inc., the Florida Company. After the merger each one of these shares were converted into 100 shares of our common stock (iHealthcare, Inc., a Delaware Company, formerly known as Opulent Acquisition, Inc). The 20,000,000 shares of common stock owned by iHealthcare, Inc., a Florida Company of iHealthcare, Inc., formerly known as Opulent Acquisition Inc., a Delaware Company were cancelled upon consummation of the merger. All share amounts are adjusted retroactively.

Currently, Noel Mijares owns 625,000 shares of our common stock and David A Bingaman owns 375,000 shares of our common stock.

The total number of authorized shares of stock that the Company is authorized to issue is 150,000,000, consisting of 143,500,000 shares of Common Stock, $0.0001 par value per share, and 6,500,000 shares of Preferred Stock, $0.0001 par value per share.

On May 13, 2016 David A. Bingaman was appointed as Chief Financial Officer, Chief Accounting Officer, and Director.

On July 25, 2016 we, Ihealthcare, Inc., organized Ihealthcare Surgical, LLC, a Florida Limited Liability Company.

On August 2, 2016 we, Ihealthcare, Inc. transferred 50% of the membership interests in Ihealthcare Surgical, LLC to All in 1 Medical, LLC per the terms of the Joint Venture agreement stated below.

Each of the aforementioned parties own 50% of the membership interests in Ihealthcare Surgical, LLC. All in 1 Medical, LLC is owned and operated by Mark Heffner, who is a non-affiliate of Ihealthcare, Inc.

As of August 31, 2016 Ihealthcare Surgical, LLC has not had any monetary transactions.

On August 19, 2016 Ihealthcare Surgical, LLC, entered into and consummated a joint venture agreement with All In 1 Medical, LLC. The purpose of the joint venture agreement is to forge a relationship that through, to be determined means, will bring together both parties in an effort to sell, to be determined, medical products. Each party retains a 50% interest in the joint venture. Each party has also agreed to split profits and expenses equally that relate to the joint venture. The term of the joint venture agreement is through August 4, 2026. It may be renewed however, for an additional five year term if agreed upon by both parties. Each party of the joint venture agreement has agreed to contribute $500 for business purposes set forth in the joint venture agreement. Neither party has, as of the date of this report, contributed the $500 however, both parties intend to make such contribution after a joint bank account is opened up for the purpose of the joint venture.

Per the above the Company has applied ASC 323 for presentation and disclosure requirements. Because Ihealthcare Surgical, LLC conducted no monetary business as of August 31, 2016 there were no transactions recorded on the books for this period.

Note 2 - Summary of Significant Accounting Policies

Principals of Consolidation

These financial statements include the accounts of the Company’s wholly owned subsidiary iHealthcare, all material intercompany balances and transactions have been eliminated.

Basis of Presentation

The accompanying unaudited consolidated ~~financial~~ financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such ~~adjustments~~ adjustments are of a normal recurring nature. These unaudited consolidated financial statements should be read in conjunction with the financial statements for the year ended November 30, ~~2015~~2016 and notes thereto.

The results of operations for the ~~nine month~~three month period ended ~~August~~February 3128, ~~2016~~2017 are not necessarily indicative of the results for the full fiscal year.

Inventories

Inventories, consisting of products available for sale, are primarily accounted for using the first-in, first-out ("FIFO") method, and are valued at the lower of cost or market value. This valuation requires ~~Ihealthcare~~iHealthcare, Inc. to make judgments, based on currently-available information, about the likely method of disposition, such as through sales to individual customers, returns to product vendors, or liquidations, and expected recoverable values of each disposition category.

Revenue Recognition

The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured.

-F4-

Table of Contents

~~Note~~NOTE 3 - GOING ~~Going Concern~~CONCERN

The Company’s unaudited ~~consolidated~~interim consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

The Company demonstrates adverse conditions that raise substantial doubt about the Company's ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, negative cash flow from operating activities, and other adverse key financial ratios.

The Company has not established any significant source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to to capital. There is no assurance that management's plan will be successful.

The unaudited interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

~~Note~~NOTE 4 - ~~Related-Party~~ ~~Transactions~~RELATED-PARTY TRANSACTIONS

Due to related party

~~Pharma~~Unisource Discovery, ~~Tropical~~Inc., ~~which~~is a related party and is controlled by our Chief Executive Officer, ~~loaned~~Noel Mijares. During the year ending November 30, 2016 Unisource Discovery Inc. advanced the Company $~~500~~6,115 ~~during~~and the ~~year~~Company ~~for~~made payment of ~~Company~~$3,805 ~~expenses~~on ~~which~~these advances. The total due to the Unisource Discovery Inc. as November 30, 2016 was ~~considered~~$2,310. ~~forgiven~~During the period ending February 28, 2017, Unisource Discovery Inc. advanced the Company $2,591 and ~~converted~~the Company made payments of $4,901 on these advances to pay ~~contributed~~the ~~capital~~balance asowed anin full . In addition, monies were transferred from the Company to ~~APIC~~Unisource Discovery Inc. totaling $1,941 for the quarter. This is listed as a loan to related party in the balance sheet. The loan is unsecured, noninterest-bearing and is payable on demand.

~~Unisource~~An ~~Discovery~~entity, ~~Inc.,~~which is ~~a related party and is~~ controlled by our Chief Executive Officer, ~~Noel~~was ~~Mijares.~~paid ~~During the period Unisource Discovery Inc. advanced the Company~~ $61,~~015~~000 ~~and~~for ~~the~~consulting ~~Company made~~expense ~~payment of $3,805 on these advances which are noninterest bearing, unsecured, and due on demand. The total due to~~ during the ~~Unisource Discovery~~quarter ~~Inc.~~ended asFebruary ~~of August 31~~28, ~~2016 is $2,210~~2017.

During the ~~nine~~year ~~month period~~ ending ~~August~~November 3130, 2016, the Company borrowed $1519,~~775~~545 from ~~the~~ ~~Chief~~its ~~Executive~~CEO ~~Officer~~ to pay for expenses on behalf of the company in the current year. and $7,500 of ~~the~~these ~~money borrowed, in addition to previous~~ payments, were posted as a reduction to subscription receivable. As of November 30, 2016, the ~~subscription~~Company ~~receivable~~was ~~owed~~indebted byto the Chief Executive Officer of the Company in the amount of $11,545. During the quarter ended February 28, 2017, our CEO advanced $5,052 and paid $1,919 in expenses on behalf of the Company totaling $6,972 for a total loan balance of $18,516 as of February 28, 2017. This loan is unsecured, noninterest-bearing and is payable on demand .

AsSubscription ~~of August 31, 2016, the Company was indebted to the Chief Executive Officer of the Company in the amount of $8,275 which is noninterest bearing, unsecured, and due on demand.~~Receivable

~~Additional~~As a ~~paid~~result of the merger in ~~capital~~2016, a subscription receivable was contributed by the principal shareholders in the amount of $34,980. The Company has collected $21,980 from the subscription receivable and converted advances of $7,500 due to the Company’s CEO as of November 30, 2016. The balance as of November 30, 2016 and February 28, 2017 is $5,500 owed by the Company’s CFO.

AsOffice a result of the merger a subscription receivable was contributed by the principal shareholders in the amount $34,800. The Company has collected $21,980 from the subscription receivable and reduced the subscription receivable by $7,500 against the loan owed by the Company to the CEO. As of August 31, 2016 the subscription receivable balance is $5,500 due by the CFO to the Company.Space

Our office space is located at 3901 NW 28th Street, 2nd Floor, Miami, FL 33142 . This space is provided to the Company rent free by Noel Mijares, who leases the office space on his personal behalf.

NOTE 5 - EQUITY

During the three months ended February 28, 2017, 79,500 shares of common stock were sold to 25 purchasers at a share price of $0.25 per share. The proceeds from the sale of stock totaled $19,875 which is recorded as $19,867 in additional paid-in capital and $8 in common stock.

NOTE 6 - SUBSEQUENT EVENTS

On March 6, 2017, 1,000 shares of common stock were sold at $0.25 per share. On March 16, 2017, 980 shares of common stock were sold at $0.25 per share. These shares were sold pursuant to the Company’s effective S-1 Registration Statement.

-F5-

Table of Contents

ITEM 2

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD LOOKING STATEMENTS

This Quarterly Report of iHealthcare, Inc. on Form 10-Q contains forward-looking statements, particularly those identified with the words, “anticipates,” “believes,” “expects,” “plans,” “intends,” “objectives,” and similar expressions. These statements reflect management's best judgment based on factors known at the time of such statements. The reader may find discussions containing such forward-looking statements in the material set forth under “Management's Discussion and Analysis of Financial Condition and Results of Operations,” generally, and specifically therein under the captions “Liquidity and Capital Resources” as well as elsewhere in this Quarterly Report on Form 10-Q. Actual events or results may differ materially from those discussed herein. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guarantee, or warranty is to be inferred from those forward-looking statements.

The assumptions used for purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and, accordingly, no opinion is expressed on the achievability of those forward-looking statements. No assurance can be given that any of the assumptions relating to the forward-looking statements specified in the following information are accurate, and we assume no obligation to update any such forward-looking statements.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

We prepare our financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends and other factors that management believes to be important at the time the financial statements are prepared. Due to the need to make estimates about the effect of matters that are inherently uncertain, materially different amounts could be reported under different conditions or using different assumptions. On a regular basis, we review our critical accounting policies and how they are applied in the preparation of our financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

PLAN OF OPERATION

~~We,~~At ~~iHealthcare,~~present ~~Inc.~~our primary ~~are~~business aactivities ~~Company~~consist ~~that~~of, ~~intends~~and torevolve ~~sell~~around, ~~and~~the ~~distribute~~sale ~~products~~of in the ~~healthcare~~UDT ~~sector.~~Cup ~~We currently~~which ~~hold~~is a ~~distribution~~urinalysis ~~agreement~~device ~~with~~used ~~Innovate~~for drug ~~Laboratory~~screening. ~~Solutions,~~Our ~~also~~sales ~~known~~of asthe ~~“ILS”~~UDT toCup ~~supply~~have usresulted ~~a product~~in ~~known~~our ascurrent ~~the~~sole ~~“UDT~~revenue ~~Cup”~~stream. ~~(also~~We ~~herein~~will ~~known~~continue asto ~~Multi-Panel~~pursue ~~[16]~~the sale ~~urinalysis~~of ~~cup~~the orUDT ~~Drug~~Cup ofas ~~Abuse “DOA”~~our ~~Cup).~~primary ~~ILS~~business ~~has~~objective. ~~agreed~~In addition to ~~provide~~our usprincipal ~~the~~business ~~right~~activities towe, ~~purchase~~and ~~the~~our subsidiary ~~UDT~~iHealthcare ~~Cup~~Surgical atLLC, ~~special~~have ~~pricing~~entered ininto ~~certain quantities.~~various ~~ILS~~business isagreements ~~the~~with ~~developer~~third ofparty ~~the~~entities ~~UDT~~as ~~Cup~~disclosed ~~and~~in our ~~exclusive~~business ~~global~~plan ~~supplier~~on ofForm ~~the~~10-K ~~UDT~~filed ~~Cup~~March 14, ~~however~~2017. ~~they~~Although we have ~~the~~yet ~~UDT~~to ~~Cup manufactured~~achieve byany arevenue ~~third~~from ~~party~~these ~~manufacturer~~activities ofwe ~~which~~are attempting ~~they~~to ~~have~~diversify ~~not~~our ~~and~~revenue ~~will~~streams ~~not~~by ~~disclose~~acting toas usa ~~due~~sales toagent ~~confidentiality.~~for ~~ILS does~~entities ~~however,~~in ~~have~~ the ~~authority~~healthcare industry, and ~~right~~ to pursue ~~control~~potential ~~who~~joint ~~manufactures the UDT Cup~~ventures.

The UDT Cup’s intended purpose is for drug screening. As of August 31, 2016 we have generated revenues in the amount of $619 to a third party as a result of the sale of UDT Cups.

On July 25, 2016 we, Ihealthcare, Inc., organized Ihealthcare Surgical, LLC, a Florida Limited Liability Company. The members of the LLC include Ihealthcare, Inc., and All in 1 Medical, LLC. Each of the aforementioned parties own 50% of the membership interests in Ihealthcare Surgical, LLC. All in 1 Medical, LLC is owned and operated by Mark Heffner, who is a non-affiliate of Ihealthcare, Inc.

On October 3, 2016 Ihealthcare Surgical, LLC entered into and consummated an agreement with Precision Spine, Inc., “Precision,” to act as Precision’s sales agent in regards to the sale of spinal implants and other medical products that are manufactured for or by Precision. Ihealthcare, Inc. is to receive a 40% commission on the sale of spinal implants for the fourth quarter of 2016 and effective January of 2017, 35%, +5% each quarter if Ihealthcare is able to generate sales of $300,000 or more in a quarterly period. For “Biologic” products as they are categorized in the agreement, Ihealthcare will receive a to be decided upon commission that is agreed upon by both parties at a later date. Regarding disposable single use instruments, Ihealthcare, Inc. will receive a 20% commission for any sales generated on Precision’s behalf.

As of August 31, 2016 Ihealthcare Surgical, LLC has not had any monetary transactions.

RESULTS OF OPERATIONS

For the three months ended ~~August~~February 3128, ~~2016~~2017 and February ~~2015~~29, 2016:

We had revenue in the three month period ending February ~~August 31~~28, ~~2016~~2017 of $~~619~~545 and $0 for the three month period ending ~~August~~February 3129, ~~2015~~2016. All of our revenues to date have been a result of sales of the UDT Cup. Our operating expenses totaled $1117,~~235~~553 ~~and~~for the three months ended February 28, 2017 and $14,~~250~~750 for the three months ended February 29, ~~respectively~~2016. Our operating expenses consisted primarily of professional fees for both periods. The variance in operating expenses is due to the fact that there have been increased professional fees for the three ~~months~~ months ended ~~August~~February 3128, ~~2016~~2017 as opposed to the ~~same~~three ~~period~~months ~~the~~ended ~~year~~February ~~prior~~29, 2016. Increased professional fees are a result of increased expenses to cover our reporting requirements. Our net loss for the three months ended ~~August~~February 3128, ~~2016~~2017 was $1017,~~901~~293 and was $14,~~250~~750 for the three months ended ~~August~~February 3129, ~~2015~~2016.

For the nine months ended August 31, 2016 and 2015:

We had revenue in the nine month period ending August 31, 2016 of $619 and $0 for the nine month period ending August 31, 2015. Our operating expenses totaled $40,561 and $4,550, respectively. Our operating expenses consisted primarily of professional fees for both periods. The variance in operating expenses is due to the fact that there have been increased professional fees for the nine months ended August 31, 2016 as opposed to the same period the year prior. Our net loss for the nine months ended August 31, 2016 was $40,227 and was $4,550 for the nine months ended August 31, 2015.

LIQUIDITY AND CAPITAL RESOURCES

We have no internal sources of liquidity. ~~Our~~at ~~only~~this ~~external source of liquidity will be our principal shareholder, iHealthcare, Inc~~time., and its officers funding our operating expenses through contributions to capital. There is no assurance of its ability to continue funding our operating expenses. There is no assurance we would be able to secure additional sources of funding. Our ability to to continue to operate is a going concern.

WeOur ~~have~~only noexternal ~~known~~sources ~~demands~~of orliquidity ~~commitments~~at ~~and~~this time are ~~not~~from ~~aware~~funds ofcontributed ~~any~~by ~~events~~our orofficers/directors ~~uncertainties~~and asfrom offunds ~~August 31, 2016 that will result~~raised infrom orthe ~~that~~sale ~~are~~of ~~reasonably likely to materially increase or decrease~~ our ~~current~~common ~~liquidity~~stock.

WeDuring the three months ended February 28, 2017, 79,500 shares of common stock were sold to 25 purchasers at a share price ~~had~~of no$.25 ~~material~~per ~~commitments~~share. ~~for~~The ~~capital~~proceeds ~~expenditures~~from asthe sale of ~~August~~stock 31totaled $19,875 ~~2016~~which ~~and~~is ~~November~~recorded 30as $19,867 ~~2015~~in additional paid-in capital and $108 in common stock.

AsThere ofis ~~August~~no ~~31,~~assurance ~~2016,~~our weofficers ~~had~~and ~~current~~directors ~~assets~~will ofbe ~~$832~~willing ~~consisting~~to ofor aable ~~combination~~to offund ~~cash~~our ~~and~~operations ~~inventory.~~for Asany duration of ~~August~~time. There ~~31,~~is ~~2016~~ also no assurance we ~~had~~will ~~current~~be ~~liabilities~~able to secure additional sources of ~~$14,525~~funding. Our ability to to continue to operate is a going concern.

We have no known demands or commitments and are not aware of any events or uncertainties as of February 28, 2017 that will result in or that are reasonably likely to materially increase or decrease our current liquidity.

We had no material commitments for capital expenditures as of February 28, 2017 and November 30, 2016.

As of February 28, 2017, we had current assets of $7,167 consisting of a combination of cash, inventory, and loans to a related party. As of February 28, 2017 we had current liabilities of $22,751.

-3-

Table of Contents

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

ITEM 3

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide the information required by this Item.

ITEM 4

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of November 30, ~~2015~~2016, have concluded that as of such date the Company’s disclosure controls and procedures were inadequate and ineffective in their design to provide reasonable assurance that material information relating to the Company would be made known to such officer on a timely basis.

For a full discussion of our internal control over financial reporting, please refer to Item 9A, “Controls and Procedures”, in our ~~2015~~2016 Annual Report on Form 10-K.

Changes in Internal Controls over Financial Reporting

There have been no changes in the Company’s internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the ~~nine~~three months ended ~~August~~February 3128, ~~2016~~2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II-OTHER INFORMATION

ITEM 1

LEGAL PROCEEDINGS

There are no legal proceedings against the Company and the Company is unaware of such proceedings contemplated against it.

ITEM 1A

RISK FACTORS

As a “smaller reporting company” defined by Item 10 of Regulation S-K, the Company is not required to provide the information required by this Item.

ITEM 2

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3

DEFAULTS UPON SENIOR SECURITIES

None.

-4-

Table of Contents

ITEM 4

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5

OTHER INFORMATION

None.

ITEM 6

EXHIBITS

(a)	Exhibits required by Item 601 of Regulation S-K.

Exhibit No.		Description
3.1		Restated Certificate of Incorporation. (1)
3.2		By-laws. (1)
10.1		Merger Agreement. (1)
10.2		Distribution Agreement with ILS (1)
31		Certification of the Company’s Chief Executive and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s report on Form 10-Q for the quarter ended ~~August~~February 3128, ~~2016~~2017. (2)
32		Certification of the Company’s Chief Executive and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)
101.INS		XBRL Instance Document (3)
101.SCH		XBRL Taxonomy Extension Schema (3)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase (3)
101.DEF		XBRL Taxonomy Extension Definition Linkbase (3)
101.LAB		XBRL Taxonomy Extension Label Linkbase (3)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase (3)

____________________

(1)	Filed as an exhibit to the Company's Form 8-K/A filed on September 8, 2016.
(2)	Filed herewith.
(3)	Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Exchange Act of 1934 and otherwise are not subject to liability.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

iHealthcare, Inc.

(Registrant)

By: /s/ Noel Mijares

Chief Executive Officer

~~President~~Dated: April 19, 2017

~~Dated~~By: ~~October~~ ~~17,~~/s/ ~~2016~~David A. Bingaman

David A. Bingaman, Chief Financial Officer

Dated: April 19, 2017

-5-

Filing Compare · iHealthcare, Inc.